Arrowhead Pharmaceuticals Inc (ARWR.O) said on Thursday Johnson & Johnson (JNJ.N) would develop and market its gene-silencing Hepatitis B drug and pick up a minor stake in the company in a deal that could be potentially worth more than $3.7 billion (2.8 billion pounds).
Under the deal, J&J's Janssen Pharmaceuticals unit will obtain a worldwide licence for Arrowhead's ARO-HBV drug and an option to collaborate on up to three new RNA interference (RNAi)drugs, which use gene-silencing technology.
J&J will make a $75 million equity investment in Arrowhead at $23 per share, a premium of about 24 percent to the company's Wednesday close. Arrowhead will also get $175 million upfront, the company said in a statement.
Arrowhead is also eligible to receive up to $1.6 billion in milestone payments for the Hepatitis B licence agreement and about $1.9 billion in option and milestone payments for the collaboration agreement related to up to three additional targets.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.